HILLSIDE, N.J., June 26, 2007 (PRIME NEWSWIRE) -- Integrated BioPharma's (Nasdaq:INBP) wholly owned subsidiary, The Organic Beverage Company, today announced the launch of its new Syzmo(tm) flavored drinks aimed at the high-growth, convenience and on-premises mainstream energy drink category. These new offerings will be widely available in mid-July. Syzmo(tm) products are currently sold through stores and distributors such as Whole Foods and Tree of Life.
"At the same time that we roll out the new flavors, we are also presenting our new packaging for this much broader distribution channel," said Jeffrey O'Neal, President of The Organic Beverage Company.
Syzmo(tm) has been recognized as the first USDA organic energy drink in the market and is now the first and only certified Glycemic Index Tested carbonated beverage in the world.
The Organic Beverage Company has been a leader in addressing the functional beverage market with healthy, alternative beverages designed to provide consumers with choices when selecting a functional beverage. The new product designs include premium blue agave nectar, organic caffeine, a full complement of RDA vitamins, pleasing taste profiles, and, importantly, no high fructose corn syrup.
Additional information on The Organic Beverage Company and its product, Syzmo(tm), can be obtained from our website, http://www.syzmo.com or by calling (866) 637-8802.
About Integrated BioPharma, Inc. (INBP)
Integrated BioPharma, Inc. is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company's biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a GMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at http://www.ibiopharma.com
Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such Statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.